6.44
+1.90%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CapsoVision
From its filings with the US Securities and Exchange Commission
CapsoVision is based in Saratoga, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CV. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $13.6m and a net loss of $25.3m. At that date it held total assets of $18.2m and shareholders' equity of $13.3m.
We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.
Building upon the commercial success and the existing design of our CapsoCam Plus capsule, we developed our next pipeline capsule endoscope, CapsoCam Colon. Our CapsoCam Colon capsule (i) leverages CapsoCam Plus’s existing capsule design with its panoramic view and (ii) incorporates both our self-developed AI to automatically detect polyps in the video and our polyp-size measurement tool enabled by a 3D sensor in the capsule (polyp size being highly correlated with a polyp’s risk of becoming cancer). We submitted the 510(k) application for our first generation CapsoCam Colon capsule to the FDA in June 2025 and received responses from the FDA in September 2025. During our meeting with the FDA in December 2025, the FDA raised inquiries on topics including panoramic image processing methodology, and the proposed study design, sample size and primary endpoint for an extended study.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 2 Jul 2025
- Employees
- 99
- Website
- capsovision.com ↗
- Head office
- 18805 COX AVENUE SUITE 250, SARATOGA, CA, 95070
- Incorporated in
- DE
- Classification
- Electromedical & Electrotherapeutic Apparatus
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Chen Lung TsaiIndependent Chairman of the Board$13,108
- Mr. Kang-Huai WangPresident, Chief Executive Officer, Co-Founder, Director, since 2006$309,704
- Mr. Douglas AtkinsonHead of Global Sales$423,700
- Ms. Rebecca PetersenSenior Director of Clinical Affairs$196,100
- Mr. Min-Liang ChenDirector
- Mr. Eliyahou HarariDirector
- Mr. Howard LeeDirector
- Ms. Heidi Chung SutardjaDirector
- Mr. Pen-Jung TsengDirector
- Ms. Julia GouwIndependent Director Nominee
- Dr. Joanne ImperialIndependent Director Nominee
- Mr. Wen-Herng KingIndependent Director Nominee
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CapsoVision operates as a commercial-stage medical technology company.
- The flagship product CapsoCam Plus uses a novel 360 panoramic lateral view.
- CapsoCloud is a next generation cloud-based software application for clinical data management.
Weaknesses
- The company has only 99 employees.
- The IPO occurred recently on 2025-07-02.
- The company is headquartered in Saratoga California.
Opportunities
- The wire-free design provides unparalleled comfort and convenience to patients.
- The capsule collection kit is a sanitary single-use kit for patients.
- The imaging solution overcomes the limitations of end-facing cameras.
Threats
- The source description is treated as untrusted facts.
- The company is in the Health Care sector and industry.
- The ISIN is US1409351079 and the ticker is CV.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.